Erratum: The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice (Atherosclerosis (2005) 181 (29-37 DOI: 10.1016/j.atherosclerosis.2004.12.028);The PPARδ agonist GW0742X reduces atherosclerosis in LDLR -/- mice

Atherosclerosis

Volumn 181, Issue 1, 2005, Pages 29-37

  Graham, Tracey L ^a   Mookherjee, Claudette ^b   Suckling, Keith E ^b   Palmer, Colin N A ^a   Patel, Lisa ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Atherosclerosis; HDL; LDLR; Macrophage; PPAR ; TNF ; VLDL

Indexed keywords

CARDIOVASCULAR AGENT; GW 0742 X; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; GW0742; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENCY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; BLOOD; BODY WEIGHT; DRUG POTENTIATION; EATING; INFLAMMATION; MACROPHAGE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AORTA; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BODY WEIGHT; EATING; INFLAMMATION; LIPIDS; LIPOPROTEINS; MACROPHAGES; MICE; MICE, KNOCKOUT; PPAR DELTA; RECEPTORS, LDL; THIAZOLES;

EID: 20444378931     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.05.014     Document Type: Erratum

References (33)

1. M. Ricote, A.F. Valledor, and C.K. Glass Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis Arterioscler Thromb Vasc Biol 24 2004 230 239
2. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors and inflammation: from basic science to clinical applications Int J Obes Relat Metab Disord 27 Suppl. 3 2003 S41 S45
3. D. Bishop-Bailey, and J. Wray Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation Prostaglandins Other Lipid Mediat 71 2003 1 22
4. M.D. Leibowitz, C. Fievet, and N. Hennuyer Activation of PPARdelta alters lipid metabolism in db/db mice FEBS Lett 473 2000 333 336
5. W.R. Oliver Jr., J.L. Shenk, and M.R. Snaith A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98 2001 5306 5311
6. G. Wolf The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis Nutr Rev 61 2003 387 390
7. U. Dressel, T.L. Allen, and J.B. Pippal The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells J Mol Endocrinol 17 2003 2477 2493
8. Y.X. Wang, C.H. Lee, and S. Tiep Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity Cell 113 2003 159 170
9. L. Cheng, G. Ding, and Q. Qin Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes Biochem Biophys Res Commun 313 2004 277 286
10. A. Chawla, C.H. Lee, and Y. Barak PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100 2003 1268 1273
11. J.F. Viles-Gonzalez, FusterV, R. Corti, and J.J. Badimon Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes Curr Opin Cardiol 18 2003 286 294
12. J.B. Hansen, H. Zhang, and T.H. Rasmussen Peroxisome proliferator- activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling J Biol Chem 276 2001 3175 3182
13. H. Vosper, L. Patel, and T. Graham The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages J Biol Chem 2001
14. J. Zhang, M. Fu, and X. Zhu Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells J Biol Chem 277 2002 11505 11512
15. N.S. Tan, L. Michalik, and N. Noy Critical roles of PPAR beta/delta in keratinocyte response to inflammation Genes Dev 15 2001 3263 3277
16. C.H. Lee, A. Chawla, and N. Urbiztondo Transcriptional repression of atherogenic inflammation: modulation by PPARdelta Science 302 2003 453 457
17. M. Merkel, W. Velez-Carrasco, L.C. Hudgins, and J.L. Breslow Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice Proc Natl Acad Sci USA 98 2001 13294 13299
18. M. Zabalawi, S. Bhat, and T. Loughlin Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol Am J Pathol 163 2003 1201 1213
19. J. Sakamoto, H. Kimura, and S. Moriyama Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochem Biophys Res Commun 278 2000 704 711
20. S.B. Joseph, E. McKilligin, and L. Pei Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proc Natl Acad Sci USA 99 2002 7604 7609
21. J. Vandesompele, K. De Preter, and F. Pattyn Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 2002 RESEARCH0034
22. J.G. DeLuca, T.W. Doebber, and L.J. Kelly Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice Mol Pharmacol 58 2000 470 476
23. M. Ammerschlaeger, J. Beigel, K.U. Klein, and S.O. Mueller Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes Toxicol Sci 78 2004 229 240
24. R.C. Cattley, J. DeLuca, and C. Elcombe Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27 1998 47 60
25. F.J. Gonzalez Recent update on the PPAR alpha-null mouse Biochimie 79 1997 139 144
26. T.E. Akiyama, G. Lambert, and C.J. Nicol Peroxisome proliferator- activated receptor beta/delta regulates very low-density lipoprotein production and catabolism in mice on a Western diet J Biol Chem 279 2004 20874 20881
27. Z. Levi, A. Shaish, and N. Yacov Rosiglitazone (PPARgamma- agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model Diabetes Obes Metab 5 2003 45 50
28. Z. Chen, S. Ishibashi, and S. Perrey Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL Arterioscler Thromb Vasc Biol 21 2001 372 377
29. A.C. Li, K.K. Brown, and M.J. Silvestre Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 2000 523 531
30. N. Marx, and V. Hombach Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells Z Kardiol 90 2001 470 477
31. S.H. Zuckerman, R.F. Kauffman, and G.F. Evans Peroxisome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice Lipids 37 2002 487 494
32. N. Terasaka, A. Hiroshima, and T. Koieyama T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice FEBS Lett 536 2003 6 11
33. A. Chawla, Y. Barak, and L. Nagy PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat Med 7 2001 48 52